Odylia Therapeutics Welcomes Joy Cavagnaro to Board of Directors
Odylia Therapeutics is pleased to announce the appointment of Joy Cavagnaro to its Board of Directors....
Odylia Therapeutics Announces Partnership with PURA Syndrome Foundation
Atlanta, GA -- December 17, 2024 Odylia Therapeutics is excited to announce a new partnership with the PURA Syndrome Foundation (PSF), a nonprofit whose mission is to support and drive research, raise awareness in the general community, as well as connect, educate, serve, and empower families...
Odylia Therapeutics Welcomes Elizabeth Attias to Board of Directors
Odylia Therapeutics is excited to announce the appointment of Elizabeth Attias to its Board of Directors....
Odylia Therapeutics Announces Partnership with Smith Kingsmore Syndrome Foundation
Smith Kingsmore Syndrome Foundation (SKSF), a nonprofit whose mission is to improve the lives of all people impacted by Smith-Kingsmore syndrome by accelerating research and connecting our global community. ...
Odylia Therapeutics Receives Translational Research Award from Foundation Fighting Blindness to Accelerate Development of Gene Therapy for RPGRIP1
Atlanta, GA, May 20, 2024 — Odylia Therapeutics, a nonprofit biotechnology company, received a Translation Research Award for $1.5 million from the Foundation Fighting Blindness to accelerate the development of a novel gene therapy (OT-004) to treat vision loss caused by mutations in the RPGRIP1...
Odylia CEO & CSO, Ashley Winslow, discusses the Nonprofit Biotech model with Talking Biotech host Kevin Folta
Atlanta, GA -- September 9, 2023 A Non-Profit Biotech Model; Therapies for Rare Diseases - Dr. Ashley Winslow By Colabra • Full Transcript • View the Website This episode has two parts. The first part discusses how Odylia Therapeutics is addressing rare disease, using a novel non-profit model....
Odylia contributes to the Affordability Guidance effort spearheaded by the Innovative Genomics Institute
In 2021, IGI’s Public Impact Team launched a year-long Affordability Task Force (ATF) project aimed at solving one of the trickiest challenges for genomic medicines. The report was released in July 2023 and "is the conclusion of a yearlong deliberation by 30 individuals with expertise...